Clinical Trial Update: Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial update evaluating the combination of osimertinib and navitoclax in patients with EGFR-positive, previously treated advanced or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Navitoclax (navitoclax)
• Osimertinib (osimertinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Phase 1 | Status: COMPLETED